Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant + Palbociclib vs Letrozole + Palbociclib in ER+, HER2- Advanced Breast Cancer
NCT04546009Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2020
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 30
01
Overview
A Phase 3 trial of giredestrant in breast cancer, sponsored by Roche. Started Oct 2020; status: active, not recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04546009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546009.